82874-96-2

Basic information

• Product Name: ETHYL 2-(METHOXYIMINO)-4-OXOPENTANOATE
• Synonyms: ETHYL 2-(METHOXYIMINO)-4-OXOPENTANOATE
• CAS NO: 82874-96-2
• Molecular Formula: C₈H₁₃NO₄
• Molecular Weight: 187.19
• Mol File: 82874-96-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ETHYL 2-(METHOXYIMINO)-4-OXOPENTANOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-(METHOXYIMINO)-4-OXOPENTANOATE(82874-96-2)
• EPA Substance Registry System: ETHYL 2-(METHOXYIMINO)-4-OXOPENTANOATE(82874-96-2)

Safety Data

• Hazardous Substances Data: 82874-96-2(Hazardous Substances Data)

Upstream product

• 593-56-6 N-methoxylamine hydrochloride 
• 615-79-2 ethyl 2,4-diketopentanoate 
• 53120-38-0 2-hydroxy-4-oxopent-2-enoic acid ethyl ester 
• 4027-57-0 ethyl 5-methyl-2H-pyrazole-3-carboxylate 
• 67-62-9 O-Methylhydroxylamin 
• 5744-40-1 ethyl 1,3-dimethylpyrazole-5-carboxylate 

Downstream Products

• 209958-57-6 2-(3-cyano-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid ethyl ester 
• 1026587-55-2 2-(2-methoxy-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid ethyl ester 
• 1027239-00-4 5-methyl-2-(2-nitro-phenyl)-2H-pyrazole-3-carboxylic acid ethyl ester 
• 330803-95-7 ethyl 3-methyl-1-(4-cyanophenyl)-1H-pyrazole-5-carboxylate 
• 209959-21-7 Ethyl [1-(3-cyano-4-fluoro)phenyl]-3-methylpyrazole-5-carboxylate 
• 868374-98-5 ethyl 3-methyl-1-(2,4,6-trichlorophenyl)-1H-pyrazole-5-carboxylate 
• 228259-05-0 ethyl 1-(2-hydroxymethyl-4-methoxyphenyl)-3-methyl-1H-pyrazole-5-carboxylate 
• 209958-55-4 ethyl 1-(3-bromophenyl)-3-methyl-pyrazol-5-yl carboxylate 
• 1027140-03-9 2-(4-cyano-3-fluoro-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid ethyl ester 
• 81153-63-1 5-methyl-2-phenyl-pyrazole-3-carboxylic acid ethyl ester 
• 218632-36-1 ethyl 1-(4-methoxyphenyl)-3-methyl-1H-pyrazole-5-carboxylate 
• 709654-29-5 ethyl 1-(3-chlorophenyl)-3-methyl-1H-pyrazole-5-carboxylate 
• 544694-75-9 1-(3-cyano-phenyl)-5-methyl-1H-pyrazole-3-carboxylic acid ethyl ester 
• 959631-17-5 2-(2,6-dichloro-phenyl)-4-isobutyl-5-methyl-2H-pyrazole-3-carboxylic acid ethyl ester 

Relevant articles and documents

Modulators of STING (Stimulator of Interferon Genes)

Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.

MACROCYCLES AS PDE1 INHIBITORS

The present invention provides macrocycles of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.

PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS

The present invention provides compounds of formula (I) that are PDEl enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

HUMAN PLASMA KALLIKREIN INHIBITORS

Disclosed are compounds of formula (I), as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

Discovery of pyrazole carboxylic acids as potent inhibitors of rat long chain l-2-hydroxy acid oxidase

Long chain l-2-hydroxy acid oxidase 2 (Hao2) is a peroxisomal enzyme expressed in the kidney and the liver. Hao2 was identified as a candidate gene for blood pressure (BP) quantitative trait locus (QTL) but the identity of its physiological substrate and its role in vivo remains largely unknown. To define a pharmacological role of this gene product, we report the development of selective inhibitors of Hao2. We identified pyrazole carboxylic acid hits 1 and 2 from screening of a compound library. Lead optimization of these hits led to the discovery of 15-XV and 15-XXXII as potent and selective inhibitors of rat Hao2. This report details the structure activity relationship of the pyrazole carboxylic acids as specific inhibitors of Hao2.

Potent and selective inhibitors of long chain l-2-hydroxy acid oxidase reduced blood pressure in DOCA salt-treated rats

l-2-Hydroxy acid oxidase (Hao2) is a peroxisomal enzyme with predominant expression in the liver and kidney. Hao2 was recently identified as a candidate gene for blood pressure quantitative trait locus in rats. To investigate a pharmacological role of Hao